NASDAQ:ZGNX - Zogenix Stock Price, Price Target & More

$39.15 -0.15 (-0.38 %)
(As of 04/26/2018 01:29 AM ET)
Previous Close$39.15
Today's Range$37.95 - $39.50
52-Week Range$10.05 - $45.85
Volume301,734 shs
Average Volume555,770 shs
Market Capitalization$1.40 billion
P/E Ratio-9.74
Dividend YieldN/A
Beta1.68

About Zogenix (NASDAQ:ZGNX)

Zogenix logoZogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome. ZX008 has received orphan drug designation in the United States and European Union (EU), for the treatment of Dravet syndrome. The Company has an additional product candidate, Relday (risperidone once-monthly long-acting injectable) for the treatment of schizophrenia. Relday is a long-acting injectable formulation of risperidone. Risperidone is used to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. It has completed the Phase I program for Relday.

Receive ZGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for ZGNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:ZGNX
CUSIP98978L10
Phone510-550-8300

Debt

Debt-to-Equity RatioN/A
Current Ratio14.52%
Quick Ratio14.52%

Price-To-Earnings

Trailing P/E Ratio-9.74
Forward P/E Ratio-12.55
P/E GrowthN/A

Sales & Book Value

Annual Sales$9.82 million
Price / Sales139.42
Cash FlowN/A
Price / CashN/A
Book Value$8.80 per share
Price / Book4.45

Profitability

EPS (Most Recent Fiscal Year)($4.02)
Net Income$-126,810,000.00
Net MarginsN/A
Return on Equity-81.65%
Return on Assets-44.22%

Miscellaneous

Employees68
Outstanding Shares34,970,000

How to Become a New Pot Stock Millionaire

Zogenix (NASDAQ:ZGNX) Frequently Asked Questions

What is Zogenix's stock symbol?

Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."

How were Zogenix's earnings last quarter?

Zogenix, Inc. (NASDAQ:ZGNX) issued its earnings results on Tuesday, March, 6th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by $0.17. During the same period in the previous year, the company posted ($0.95) EPS. View Zogenix's Earnings History.

What price target have analysts set for ZGNX?

5 equities research analysts have issued 12 month target prices for Zogenix's shares. Their forecasts range from $51.00 to $56.00. On average, they expect Zogenix's stock price to reach $54.00 in the next twelve months. View Analyst Ratings for Zogenix.

What are Wall Street analysts saying about Zogenix stock?

Here are some recent quotes from research analysts about Zogenix stock:
  • 1. According to Zacks Investment Research, "Zogenix, Inc. is a pharmaceutical company engaged in the development and commercialization of treatment products for central nervous system disorders and pain. Its first commercial product, Sumavel™ DosePro™ is a needle-free Delivery System used in the treatment of acute migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, ZX002, is a novel, oral and single-entity controlled-release formulation of hydrocodone used for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix, Inc. is headquartered in San Diego, CA. " (3/15/2018)
  • 2. Mizuho analysts commented, "We believe the Breakthrough designation is likely to expedite the review process for the DS indication." (3/7/2018)

Who are some of Zogenix's key competitors?

Who are Zogenix's key executives?

Zogenix's management team includes the folowing people:
  • Cam L. Garner, Independent Chairman of the Board (Age 67)
  • Stephen J. Farr Ph.D., President, Chief Executive Officer, Director (Age 58)
  • Michael P. Smith, Chief Financial Officer, Executive Vice President, Treasurer, Secretary (Age 48)
  • Gail M. Farfel Ph.D., Executive Vice President, Chief Development Officer (Age 51)
  • Bradley S. Galer M.D., Executive Vice President and Chief Medical Officer (Age 53)
  • James B. Breitmeyer M.D., Ph.D., Director (Age 61)
  • Roger L. Hawley, Director (Age 63)
  • Erle T. Mast, Independent Director (Age 52)
  • Mark C. Wiggins, Independent Director (Age 59)

Has Zogenix been receiving favorable news coverage?

News coverage about ZGNX stock has been trending somewhat positive this week, Accern reports. The research group rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Zogenix earned a media sentiment score of 0.09 on Accern's scale. They also gave media stories about the company an impact score of 44.63 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Zogenix?

Shares of ZGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zogenix's stock price today?

One share of ZGNX stock can currently be purchased for approximately $39.15.

How big of a company is Zogenix?

Zogenix has a market capitalization of $1.40 billion and generates $9.82 million in revenue each year. The company earns $-126,810,000.00 in net income (profit) each year or ($4.02) on an earnings per share basis. Zogenix employs 68 workers across the globe.

How can I contact Zogenix?

Zogenix's mailing address is 5858 Horton Street Suite 455, EMERYVILLE CA, 94608. The company can be reached via phone at 510-550-8300 or via email at [email protected]


MarketBeat Community Rating for Zogenix (ZGNX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  264 (Vote Outperform)
Underperform Votes:  169 (Vote Underperform)
Total Votes:  433
MarketBeat's community ratings are surveys of what our community members think about Zogenix and other stocks. Vote "Outperform" if you believe ZGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Zogenix (NASDAQ:ZGNX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Zogenix in the last 12 months. Their average twelve-month price target is $54.00, suggesting that the stock has a possible upside of 37.93%. The high price target for ZGNX is $56.00 and the low price target for ZGNX is $51.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $54.00$54.00$48.00$46.00
Price Target Upside: 37.93% upside22.73% upside40.76% upside31.24% upside

Zogenix (NASDAQ:ZGNX) Consensus Price Target History

Price Target History for Zogenix (NASDAQ:ZGNX)

Zogenix (NASDAQ:ZGNX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/7/2018MizuhoReiterated RatingBuy$51.00HighView Rating Details
3/4/2018Leerink SwannReiterated RatingOutperformHighView Rating Details
11/27/2017JMP SecuritiesInitiated CoverageOutperform$56.00MediumView Rating Details
9/29/2017Stifel NicolausReiterated RatingBuy$26.00 -> $55.00N/AView Rating Details
9/29/2017William BlairUpgradeMarket Perform -> OutperformN/AView Rating Details
3/11/2017AegisReiterated RatingBuy$28.00N/AView Rating Details
9/21/2016Brean CapitalReiterated RatingBuy$28.00N/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Zogenix (NASDAQ:ZGNX) Earnings History and Estimates Chart

Earnings by Quarter for Zogenix (NASDAQ:ZGNX)

Zogenix (NASDAQ:ZGNX) Earnings Estimates

2018 EPS Consensus Estimate: ($2.98)
2019 EPS Consensus Estimate: ($3.42)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.78)($0.66)($0.72)
Q2 20182($0.79)($0.70)($0.75)
Q3 20182($0.76)($0.72)($0.74)
Q4 20182($0.81)($0.74)($0.78)
Q1 20191($0.91)($0.91)($0.91)
Q2 20191($0.92)($0.92)($0.92)
Q3 20191($0.84)($0.84)($0.84)
Q4 20191($0.75)($0.75)($0.75)

Zogenix (NASDAQ ZGNX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2018Q4 2017($0.97)($1.14)ViewListenView Earnings Details
11/7/2017Q3 2017($0.95)($1.11)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.89)($0.90)$3.48 million$7.10 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.88)($0.85)$4.23 million$2.70 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.84)($0.73)$5.05 million$10.99 millionViewN/AView Earnings Details
11/7/2016Q3($0.96)($0.69)$3.10 million$6.57 millionViewListenView Earnings Details
8/9/2016Q216($0.81)($0.76)$5.36 million$2.10 millionViewN/AView Earnings Details
5/10/2016Q116($0.62)($0.42)$4.90 million$9.20 millionViewListenView Earnings Details
3/10/2016Q415($0.69)($0.36)$6.39 million$6.10 millionViewListenView Earnings Details
11/9/2015Q315($0.74)($0.65)$5.90 million$9.12 millionViewN/AView Earnings Details
8/10/2015Q215($0.77)$3.78$5.13 million$7.40 millionViewListenView Earnings Details
5/11/2015Q115($0.13)($0.15)$8.54 million$4.60 millionViewListenView Earnings Details
3/10/2015Q414($0.11)($0.13)$11.50 million$14.90 millionViewListenView Earnings Details
11/6/2014Q314($0.16)($0.15)$8.30 million$8.80 millionViewListenView Earnings Details
8/5/2014Q214($0.16)($0.19)$9.84 million$9.16 millionViewListenView Earnings Details
5/8/2014Q114($0.17)($0.20)$8.71 million$7.70 millionViewListenView Earnings Details
3/5/2014Q413($0.09)($0.13)$8.68 million$9.90 millionViewListenView Earnings Details
11/4/2013Q313($0.09)($0.12)$9.33 million$7.20 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.15)($0.13)$8.63 million$8.90 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.14)($0.21)$9.28 million$7.00 millionViewListenView Earnings Details
3/15/2013Q4 2012($0.17)($0.16)$9.87 million$9.50 millionViewListenView Earnings Details
11/8/2012Q312($0.16)($0.16)$9.98 million$8.50 millionViewN/AView Earnings Details
8/8/2012($0.28)($0.26)ViewN/AView Earnings Details
5/14/2012($0.14)($0.16)ViewN/AView Earnings Details
3/8/2012($0.36)($0.36)ViewN/AView Earnings Details
11/10/2011($0.55)($0.59)ViewN/AView Earnings Details
8/10/2011Q2 2011($4.16)($4.51)ViewN/AView Earnings Details
5/16/2011($0.50)($0.56)ViewN/AView Earnings Details
3/3/2011($0.62)($0.04)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Zogenix (NASDAQ:ZGNX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Zogenix (NASDAQ ZGNX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.60%
Insider Trading History for Zogenix (NASDAQ:ZGNX)
Institutional Ownership by Quarter for Zogenix (NASDAQ:ZGNX)

Zogenix (NASDAQ ZGNX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/13/2018Roger HawleyDirectorSell35,000$44.71$1,564,850.00View SEC Filing  
12/13/2017Bradley S. GalerEVPBuy1,346$36.59$49,250.14View SEC Filing  
12/11/2017Roger HawleyDirectorSell63,203$36.84$2,328,398.52105,575View SEC Filing  
12/8/2017Roger HawleyDirectorSell11,797$37.02$436,724.94105,575View SEC Filing  
10/3/2017Life Sciences Maste PerceptiveMajor ShareholderBuy300,000$37.50$11,250,000.00View SEC Filing  
9/29/2017Life Sciences Maste PerceptiveMajor ShareholderBuy222,055$32.83$7,290,065.65View SEC Filing  
6/30/2017Life Sciences Maste PerceptiveMajor ShareholderBuy175,653$14.45$2,538,185.85View SEC Filing  
3/16/2017Renee P TannenbaumDirectorBuy5,000$11.00$55,000.0010,000View SEC Filing  
12/15/2015Roger HawleyDirectorBuy10,000$13.74$137,400.001,404,447View SEC Filing  
6/13/2014Cam L GarnerDirectorBuy30,000$1.66$49,800.00View SEC Filing  
6/3/2014Ann D RhoadsCFOSell19,229$2.10$40,380.90View SEC Filing  
6/3/2014Roger HawleyCEOSell25,078$2.10$52,663.80View SEC Filing  
6/3/2014Stephen J FarrCOOSell20,900$2.10$43,890.00View SEC Filing  
11/20/2013Richard Scott ShivelyInsiderBuy67,000$2.79$186,930.0079,500View SEC Filing  
12/13/2012Cynthia Y RobinsonInsiderBuy50,000$1.17$58,500.00View SEC Filing  
12/12/2012Ann D RhoadsCFOBuy17,500$1.19$20,825.00View SEC Filing  
12/12/2012Cam L GarnerDirectorBuy70,000$1.21$84,700.00View SEC Filing  
12/11/2012Erle T MastDirectorBuy10,000$1.15$11,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Zogenix (NASDAQ ZGNX) News Headlines

Source:
DateHeadline
Report: Exploring Fundamental Drivers Behind Urban Edge Properties, FLIR, Zogenix, Watts Water Technologies ...Report: Exploring Fundamental Drivers Behind Urban Edge Properties, FLIR, Zogenix, Watts Water Technologies ...
globenewswire.com - April 25 at 8:46 AM
Zogenix Announces Presentation of New Efficacy and Safety Data from its First Pivotal Phase 3 Clinical Trial of ZX008 ...Zogenix Announces Presentation of New Efficacy and Safety Data from its First Pivotal Phase 3 Clinical Trial of ZX008 ...
globenewswire.com - April 25 at 8:46 AM
BRIEF-Zogenix Announces Presentation Of New Efficacy And Safety Data From Its First Pivotal Phase 3 Clinical Trial Of ...BRIEF-Zogenix Announces Presentation Of New Efficacy And Safety Data From Its First Pivotal Phase 3 Clinical Trial Of ...
www.reuters.com - April 25 at 8:46 AM
Zogenix (ZGNX) Upgraded by BidaskClub to "Buy"Zogenix (ZGNX) Upgraded by BidaskClub to "Buy"
www.americanbankingnews.com - April 20 at 11:17 AM
Stock Traders Purchase High Volume of Zogenix Put Options (ZGNX)Stock Traders Purchase High Volume of Zogenix Put Options (ZGNX)
www.americanbankingnews.com - April 20 at 7:13 AM
Zogenix Target of Unusually Large Options Trading (ZGNX)Zogenix Target of Unusually Large Options Trading (ZGNX)
www.americanbankingnews.com - April 20 at 7:08 AM
Zogenix, Inc. (ZGNX) Given Average Rating of "Buy" by BrokeragesZogenix, Inc. (ZGNX) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 20 at 5:35 AM
Zogenix, Inc. (ZGNX) Expected to Post Earnings of -$0.74 Per ShareZogenix, Inc. (ZGNX) Expected to Post Earnings of -$0.74 Per Share
www.americanbankingnews.com - April 20 at 5:21 AM
KOL Epilepsy Lunch Confirms Zogenix (ZGNX) Fenfluramine Efficacy - StifelKOL Epilepsy Lunch Confirms Zogenix (ZGNX) Fenfluramine Efficacy - Stifel
www.streetinsider.com - April 19 at 8:46 AM
Brokers Issue Forecasts for Zogenix, Inc.s FY2019 Earnings (ZGNX)Brokers Issue Forecasts for Zogenix, Inc.'s FY2019 Earnings (ZGNX)
www.americanbankingnews.com - April 18 at 8:52 AM
Zogenix (ZGNX) Rating Lowered to Buy at BidaskClubZogenix (ZGNX) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - April 17 at 12:21 PM
Zogenix to Participate in LEERINK Partners CNS DayZogenix to Participate in LEERINK Partners CNS Day
finance.yahoo.com - April 11 at 9:13 AM
Zogenix (ZGNX) Lowered to "Hold" at BidaskClubZogenix (ZGNX) Lowered to "Hold" at BidaskClub
www.americanbankingnews.com - April 10 at 3:25 PM
Zogenix (ZGNX) Upgraded to "Hold" by ValuEngineZogenix (ZGNX) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - April 10 at 8:47 AM
Forty Seven, Inc. Appoints Ann D. Rhoads as Chief Financial OfficerForty Seven, Inc. Appoints Ann D. Rhoads as Chief Financial Officer
www.prnewswire.com - April 3 at 8:57 AM
Zogenix (ZGNX) Upgraded at ValuEngineZogenix (ZGNX) Upgraded at ValuEngine
www.americanbankingnews.com - April 2 at 10:26 PM
Wired News – Shire Collaborates with NanoMedSyn to Treat Potential Lysosomal Storage DisorderWired News – Shire Collaborates with NanoMedSyn to Treat Potential Lysosomal Storage Disorder
finance.yahoo.com - March 28 at 9:02 AM
Zogenix, Inc. (ZGNX) Given Consensus Rating of "Buy" by AnalystsZogenix, Inc. (ZGNX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 26 at 5:40 AM
Zogenix (ZGNX) Given Buy Rating at MizuhoZogenix (ZGNX) Given Buy Rating at Mizuho
www.americanbankingnews.com - March 25 at 10:22 PM
Zogenix (ZGNX) Rating Increased to Buy at Zacks Investment ResearchZogenix (ZGNX) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 15 at 12:50 PM
Zogenix, Inc. (ZGNX) Director Sells $1,564,850.00 in StockZogenix, Inc. (ZGNX) Director Sells $1,564,850.00 in Stock
www.americanbankingnews.com - March 14 at 7:12 PM
Zogenixs (ZGNX) Buy Rating Reaffirmed at MizuhoZogenix's (ZGNX) Buy Rating Reaffirmed at Mizuho
www.americanbankingnews.com - March 11 at 1:16 PM
Employee Stock Options Liability Significant For ZogenixEmployee Stock Options Liability Significant For Zogenix
finance.yahoo.com - March 9 at 6:13 PM
Q1 2018 EPS Estimates for Zogenix, Inc. (ZGNX) Raised by AnalystQ1 2018 EPS Estimates for Zogenix, Inc. (ZGNX) Raised by Analyst
www.americanbankingnews.com - March 9 at 8:52 AM
Zogenix, Inc. (ZGNX) Expected to Earn Q1 2018 Earnings of ($0.78) Per ShareZogenix, Inc. (ZGNX) Expected to Earn Q1 2018 Earnings of ($0.78) Per Share
www.americanbankingnews.com - March 9 at 8:52 AM
Zogenix, Inc. (ZGNX) Forecasted to Earn Q1 2019 Earnings of ($0.91) Per ShareZogenix, Inc. (ZGNX) Forecasted to Earn Q1 2019 Earnings of ($0.91) Per Share
www.americanbankingnews.com - March 8 at 11:28 AM
Why Zogenix Inc. Shares Shot Up 16.6% in February - Motley FoolWhy Zogenix Inc. Shares Shot Up 16.6% in February - Motley Fool
www.fool.com - March 7 at 5:56 PM
Zogenix (ZGNX) Releases  Earnings Results, Misses Expectations By $0.17 EPSZogenix (ZGNX) Releases Earnings Results, Misses Expectations By $0.17 EPS
www.americanbankingnews.com - March 7 at 1:25 PM
Zogenix (ZGNX) Stock Rating Reaffirmed by Leerink SwannZogenix (ZGNX) Stock Rating Reaffirmed by Leerink Swann
www.americanbankingnews.com - March 7 at 11:33 AM
Zogenix, Inc. Forecasted to Post FY2017 Earnings of ($4.17) Per Share (ZGNX)Zogenix, Inc. Forecasted to Post FY2017 Earnings of ($4.17) Per Share (ZGNX)
www.americanbankingnews.com - March 7 at 7:26 AM
Why Zogenix Inc. Shares Shot Up 16.6% in FebruaryWhy Zogenix Inc. Shares Shot Up 16.6% in February
finance.yahoo.com - March 6 at 5:18 PM
Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial ResultsZogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results
finance.yahoo.com - March 6 at 5:18 PM
Zogenix, Inc. (ZGNX) is VHCP Management II LLCs 5th Largest PositionZogenix, Inc. (ZGNX) is VHCP Management II LLC's 5th Largest Position
www.americanbankingnews.com - March 6 at 10:31 AM
Bogle Investment Management L P DE Takes Position in Zogenix, Inc. (ZGNX)Bogle Investment Management L P DE Takes Position in Zogenix, Inc. (ZGNX)
www.americanbankingnews.com - March 6 at 5:04 AM
Why Earnings Season Could Be Great for Zogenix (ZGNX)Why Earnings Season Could Be Great for Zogenix (ZGNX)
finance.yahoo.com - March 5 at 5:30 PM
State of Wisconsin Investment Board Buys 12,600 Shares of Zogenix, Inc. (ZGNX)State of Wisconsin Investment Board Buys 12,600 Shares of Zogenix, Inc. (ZGNX)
www.americanbankingnews.com - March 5 at 9:43 AM
Emory University Trims Holdings in Zogenix, Inc. (ZGNX)Emory University Trims Holdings in Zogenix, Inc. (ZGNX)
www.americanbankingnews.com - March 4 at 2:59 PM
Zogenix, Inc. (ZGNX) Shares Sold by Gagnon Securities LLCZogenix, Inc. (ZGNX) Shares Sold by Gagnon Securities LLC
www.americanbankingnews.com - March 3 at 3:01 PM
Zogenix, Inc. (ZGNX) Shares Bought by Broadfin Capital LLCZogenix, Inc. (ZGNX) Shares Bought by Broadfin Capital LLC
www.americanbankingnews.com - March 2 at 5:08 AM
Ascend Capital LLC Sells 132,867 Shares of Zogenix, Inc. (ZGNX)Ascend Capital LLC Sells 132,867 Shares of Zogenix, Inc. (ZGNX)
www.americanbankingnews.com - March 2 at 5:06 AM
Report: Developing Opportunities within Inseego, Cato, FleetCor Technologies, Zogenix, Verisk Analytics, and XPO Logistics — Future Expectations, Projections Moving into 2018Report: Developing Opportunities within Inseego, Cato, FleetCor Technologies, Zogenix, Verisk Analytics, and XPO Logistics — Future Expectations, Projections Moving into 2018
finance.yahoo.com - March 1 at 8:40 AM
Zogenix, Inc. (ZGNX) Given Consensus Rating of "Buy" by BrokeragesZogenix, Inc. (ZGNX) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 1 at 5:30 AM
Carillon Tower Advisers Inc. Buys New Position in Zogenix, Inc. (ZGNX)Carillon Tower Advisers Inc. Buys New Position in Zogenix, Inc. (ZGNX)
www.americanbankingnews.com - February 28 at 5:26 AM
 Brokerages Expect Zogenix, Inc. (ZGNX) to Post -$1.01 Earnings Per Share Brokerages Expect Zogenix, Inc. (ZGNX) to Post -$1.01 Earnings Per Share
www.americanbankingnews.com - February 28 at 3:14 AM
EAM Investors LLC Has $4.30 Million Stake in Zogenix, Inc. (ZGNX)EAM Investors LLC Has $4.30 Million Stake in Zogenix, Inc. (ZGNX)
www.americanbankingnews.com - February 27 at 3:10 PM
Zogenix to Release Fourth Quarter and Full-Year 2017 Financial Results and Host Conference Call and Webcast on March 6Zogenix to Release Fourth Quarter and Full-Year 2017 Financial Results and Host Conference Call and Webcast on March 6
finance.yahoo.com - February 27 at 8:50 AM
Leerink Swann Increases Zogenix (ZGNX) Price Target to $54.00Leerink Swann Increases Zogenix (ZGNX) Price Target to $54.00
www.americanbankingnews.com - February 23 at 6:06 PM
Zogenix (ZGNX) Presents At Leerink Partners 7th Annual Global Healthcare Conference - SlideshowZogenix (ZGNX) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - February 16 at 5:00 PM
BidaskClub Upgrades Zogenix (ZGNX) to "Buy"BidaskClub Upgrades Zogenix (ZGNX) to "Buy"
www.americanbankingnews.com - February 10 at 7:24 AM
Stock Traders Buy Large Volume of Call Options on Zogenix (ZGNX)Stock Traders Buy Large Volume of Call Options on Zogenix (ZGNX)
www.americanbankingnews.com - February 9 at 1:10 AM

SEC Filings

Zogenix (NASDAQ:ZGNX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Zogenix (NASDAQ:ZGNX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Zogenix (NASDAQ ZGNX) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.